FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W55479178> ?p ?o ?g. }

• W55479178 endingPage "5692" @default.
• W55479178 startingPage "5692" @default.
• W55479178 abstract "To evaluate pegylated interferon alpha2a (PegIFN-alpha2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate.A total of 73 naive patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed.Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-alpha2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response between bilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable.PegIFN-alpha2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation." @default.
• W55479178 created "2016-06-24" @default.
• W55479178 creator A5006861492 @default.
• W55479178 creator A5020190321 @default.
• W55479178 creator A5026944567 @default.
• W55479178 creator A5031755512 @default.
• W55479178 creator A5037763123 @default.
• W55479178 creator A5043306214 @default.
• W55479178 creator A5070237025 @default.
• W55479178 creator A5070601934 @default.
• W55479178 creator A5073356686 @default.
• W55479178 creator A5086748965 @default.
• W55479178 date "2006-01-01" @default.
• W55479178 modified "2023-10-09" @default.
• W55479178 title "Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage" @default.
• W55479178 cites W102032512 @default.
• W55479178 cites W1524194013 @default.
• W55479178 cites W1972999051 @default.
• W55479178 cites W1981701184 @default.
• W55479178 cites W1985462000 @default.
• W55479178 cites W1995326699 @default.
• W55479178 cites W2002734786 @default.
• W55479178 cites W2004029202 @default.
• W55479178 cites W2004800330 @default.
• W55479178 cites W2011707824 @default.
• W55479178 cites W2018446644 @default.
• W55479178 cites W2027545702 @default.
• W55479178 cites W2031331647 @default.
• W55479178 cites W2032588916 @default.
• W55479178 cites W2044984157 @default.
• W55479178 cites W2045390938 @default.
• W55479178 cites W2060338814 @default.
• W55479178 cites W2061294380 @default.
• W55479178 cites W2064974925 @default.
• W55479178 cites W2065960044 @default.
• W55479178 cites W2066915530 @default.
• W55479178 cites W2076997221 @default.
• W55479178 cites W2095206832 @default.
• W55479178 cites W2097932782 @default.
• W55479178 cites W2137069051 @default.
• W55479178 cites W2156047935 @default.
• W55479178 cites W2164454925 @default.
• W55479178 cites W2165297688 @default.
• W55479178 cites W2165889558 @default.
• W55479178 cites W2416495316 @default.
• W55479178 doi "https://doi.org/10.3748/wjg.v12.i35.5692" @default.
• W55479178 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4088172" @default.
• W55479178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17007024" @default.
• W55479178 hasPublicationYear "2006" @default.
• W55479178 type Work @default.
• W55479178 sameAs 55479178 @default.
• W55479178 citedByCount "41" @default.
• W55479178 countsByYear W554791782012 @default.
• W55479178 countsByYear W554791782013 @default.
• W55479178 countsByYear W554791782014 @default.
• W55479178 countsByYear W554791782015 @default.
• W55479178 countsByYear W554791782016 @default.
• W55479178 countsByYear W554791782017 @default.
• W55479178 countsByYear W554791782019 @default.
• W55479178 crossrefType "journal-article" @default.
• W55479178 hasAuthorship W55479178A5006861492 @default.
• W55479178 hasAuthorship W55479178A5020190321 @default.
• W55479178 hasAuthorship W55479178A5026944567 @default.
• W55479178 hasAuthorship W55479178A5031755512 @default.
• W55479178 hasAuthorship W55479178A5037763123 @default.
• W55479178 hasAuthorship W55479178A5043306214 @default.
• W55479178 hasAuthorship W55479178A5070237025 @default.
• W55479178 hasAuthorship W55479178A5070601934 @default.
• W55479178 hasAuthorship W55479178A5073356686 @default.
• W55479178 hasAuthorship W55479178A5086748965 @default.
• W55479178 hasBestOaLocation W554791781 @default.
• W55479178 hasConcept C126322002 @default.
• W55479178 hasConcept C142462285 @default.
• W55479178 hasConcept C203014093 @default.
• W55479178 hasConcept C2522874641 @default.
• W55479178 hasConcept C2776178377 @default.
• W55479178 hasConcept C2776408679 @default.
• W55479178 hasConcept C2776461080 @default.
• W55479178 hasConcept C2780040827 @default.
• W55479178 hasConcept C2780559512 @default.
• W55479178 hasConcept C2781228144 @default.
• W55479178 hasConcept C2781413609 @default.
• W55479178 hasConcept C2909179924 @default.
• W55479178 hasConcept C71924100 @default.
• W55479178 hasConcept C90924648 @default.
• W55479178 hasConceptScore W55479178C126322002 @default.
• W55479178 hasConceptScore W55479178C142462285 @default.
• W55479178 hasConceptScore W55479178C203014093 @default.
• W55479178 hasConceptScore W55479178C2522874641 @default.
• W55479178 hasConceptScore W55479178C2776178377 @default.
• W55479178 hasConceptScore W55479178C2776408679 @default.
• W55479178 hasConceptScore W55479178C2776461080 @default.
• W55479178 hasConceptScore W55479178C2780040827 @default.
• W55479178 hasConceptScore W55479178C2780559512 @default.
• W55479178 hasConceptScore W55479178C2781228144 @default.
• W55479178 hasConceptScore W55479178C2781413609 @default.
• W55479178 hasConceptScore W55479178C2909179924 @default.
• W55479178 hasConceptScore W55479178C71924100 @default.

• next